{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T11:51:53Z","timestamp":1648554713936},"reference-count":11,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T00:00:00Z","timestamp":1540252800000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"National Institutes of Health National Center for Advancing Translational Science","award":["UL1TR001881"],"award-info":[{"award-number":["UL1TR001881"]}]},{"name":"NIH Heart, Lung, and Blood Institute","award":["K08HL133491"],"award-info":[{"award-number":["K08HL133491"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,12,1]]},"DOI":"10.1093\/ehjcr\/yty108","type":"journal-article","created":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T06:35:01Z","timestamp":1540276501000},"source":"Crossref","is-referenced-by-count":0,"title":["Case series: clinical outcomes of the transthyretin valine-to-isoleucine mutation in a brother\u2013sister pair"],"prefix":"10.1093","volume":"2","author":[{"given":"Jason Y","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Medicine, Geffen School of Medicine, University of California, 10833 Le Conte Avenue Los Angeles, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Afrida","family":"Sara","sequence":"additional","affiliation":[{"name":"Clinical and Translational Science Institute, Geffen School of Medicine, University of California, Los Angeles, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jar-Yee","family":"Liu","sequence":"additional","affiliation":[{"name":"Clinical and Translational Science Institute, Geffen School of Medicine, University of California, Los Angeles, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith","family":"Fan","sequence":"additional","affiliation":[{"name":"Institute for Precision Health, Geffen School of Medicine, University of California, Los Angeles, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pritha","family":"Gupta","sequence":"additional","affiliation":[{"name":"Department of Medicine, Geffen School of Medicine, University of California, 10833 Le Conte Avenue Los Angeles, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Medicine, Geffen School of Medicine, University of California, 10833 Le Conte Avenue Los Angeles, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2018,10,22]]},"reference":[{"key":"key\n\t\t\t\t2019032003033046200_yty108-B1","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3109\/13506129.2015.1051219","article-title":"Prevalence of the amyloidogenic transthyretin (TTR) V122I allele in 14 333 African-Americans","volume":"22","author":"Jacobson","year":"2015","journal-title":"Amyloid"},{"key":"key\n\t\t\t\t2019032003033046200_yty108-B2","doi-asserted-by":"crossref","first-page":"14943","DOI":"10.1073\/pnas.261419998","article-title":"The V122I cardiomyopathy variant of transthyretin increases the velocity of rate-limiting tetramer dissociation, resulting in accelerated amyloidosis","volume":"98","author":"Jiang","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"key\n\t\t\t\t2019032003033046200_yty108-B3","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1056\/NEJMoa1404852","article-title":"The amyloidogenic V122I transthyretin variant in elderly black Americans","volume":"372","author":"Quarta","year":"2015","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019032003033046200_yty108-B4","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jmoldx.2013.08.001","article-title":"Homozygosity for the V122I mutation in transthyretin is associated with earlier onset of cardiac amyloidosis in the African American population in the seventh decade of life","volume":"16","author":"Reddi","year":"2014","journal-title":"J Mol Diagn"},{"key":"key\n\t\t\t\t2019032003033046200_yty108-B5","doi-asserted-by":"crossref","first-page":"53483","DOI":"10.1074\/jbc.M408053200","article-title":"The crystal structure of transthyretin in complex with diethylstilbestrol: a promising template for the design of amyloid inhibitors","volume":"279","author":"Morais-de-Sa","year":"2004","journal-title":"J Biol Chem"},{"key":"key\n\t\t\t\t2019032003033046200_yty108-B6","doi-asserted-by":"crossref","first-page":"14545","DOI":"10.1073\/pnas.0501609102","article-title":"Genistein, a natural product from soy, is a potent inhibitor of transthyretin amyloidosis","volume":"102","author":"Green","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"key\n\t\t\t\t2019032003033046200_yty108-B7","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s10741-014-9462-7","article-title":"Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs","volume":"20","author":"Castano","year":"2015","journal-title":"Heart Fail Rev"},{"key":"key\n\t\t\t\t2019032003033046200_yty108-B8","doi-asserted-by":"crossref","first-page":"181.","DOI":"10.1186\/s12883-017-0948-5","article-title":"Trial design and rationale for APOLLO, a Phase 3, placebo-controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy","volume":"17","author":"Adams","year":"2017","journal-title":"BMC Neurol"},{"key":"key\n\t\t\t\t2019032003033046200_yty108-B9","doi-asserted-by":"crossref","first-page":"9629","DOI":"10.1073\/pnas.1121005109","article-title":"Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade","volume":"109","author":"Bulawa","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"key\n\t\t\t\t2019032003033046200_yty108-B10","first-page":"1007","article-title":"Tafamadis treatment for patients with transthyretin amyloid cardiomyopathy","volume-title":"N Engl J Med","author":"Maurer","year":"2018"},{"key":"key\n\t\t\t\t2019032003033046200_yty108-B11","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N Engl J Med"}],"container-title":["European Heart Journal - Case Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ehjcr\/article-pdf\/2\/4\/yty108\/28122808\/yty108.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,20]],"date-time":"2019-03-20T07:06:17Z","timestamp":1553065577000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcr\/article\/doi\/10.1093\/ehjcr\/yty108\/5142402"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,22]]},"references-count":11,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2018,10,22]]},"published-print":{"date-parts":[[2018,12,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcr\/yty108","relation":{},"ISSN":["2514-2119"],"issn-type":[{"value":"2514-2119","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,12]]},"published":{"date-parts":[[2018,10,22]]}}}